Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $13,095.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 2,700 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $13,095.00. Following the completion of the transaction, the insider directly owned 283,852 shares in the company, valued at $1,376,682.20. This trade represents a 0.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded down $0.04 during midday trading on Wednesday, hitting $4.86. The stock had a trading volume of 71,758 shares, compared to its average volume of 188,492. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The company has a market capitalization of $332.86 million, a PE ratio of -9.53 and a beta of 1.04. The firm’s fifty day moving average is $4.78 and its two-hundred day moving average is $4.68. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter worth $55,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $54,000. Archon Capital Management LLC increased its holdings in SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after acquiring an additional 14,342 shares during the last quarter. Renaissance Technologies LLC lifted its stake in SOPHiA GENETICS by 169.5% in the 4th quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock worth $388,000 after purchasing an additional 52,200 shares in the last quarter. Finally, Polen Capital Management LLC bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $102,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim boosted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Multiple insiders executed pre-arranged Rule 10b5-1 sales to cover tax obligations — CEO Jurgi Camblong, President Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others. Collectively ~25,000 shares were sold over April 6–7 for roughly $120k at an average price near $4.85–$4.88. Executives still retain large positions, and filings note these were routine plan-driven sales rather than opportunistic exits. CEO Form 4 President Form 4 Insider Form 4

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.